Agios Pharmaceuticals Inc. (AGIO), a commercial-stage company pioneering therapies for rare diseases, is anticipated to release crucial clinical trial data by the end of this year, making it an event to keep an eye on.
The scheduled data presentation includes results from the phase IIa segment of a phase IIa/IIb multicenter, efficacy, and safety study of AG-946 in participants with anemia due to lower-risk myelodysplastic syndromes.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com